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Summary
One explanation for the weak relationship between neu-
ropsychological de®cits and conventional measures of
disease burden in multiple sclerosis is that brain `plasti-
city' allows adaptive reorganization of cognitive func-
tions to limit impairment, despite injury. We have tested
this hypothesis. Ten patients with multiple sclerosis and
11 healthy controls were studied using a functional MRI
(fMRI) counting Stroop task. The two subject groups
had comparable performances, but a predominantly left
medial prefrontal region [Brodmann area (BA) 8/9/10]
was more active during the task in patients than in con-
trols (corrected P < 0.001), while a right frontal region
(including BA 45 and the basal ganglia) was more active
in controls than in patients (corrected P = 0.004). The
magnitude of the differences correlated with the normal-
ized brain parenchymal volume, a measure of disease
burden (r = ±0.72, P = 0.02). We then tested the effects of
acute administration of rivastigmine, a central cholines-
terase inhibitor, on patterns of brain activation. In ®ve
out of ®ve multiple sclerosis patients there was a relative
normalization of the abnormal Stroop-associated brain
activation, although no change in the patterns of brain
activation was found in any of four healthy controls
given the drug and tested in the same way. We suggest
that recruitment of medial prefrontal cortex is a form of
adaptive brain plasticity that compensates, in part, for
relative de®cits in processing related to the reduced
right prefrontal cortex activity with multiple sclerosis.
This functional plasticity is modulated by cholinergic
agonism and must arise from potentially highly dynamic
mechanisms such as the `unmasking' of latent pathways.
Keywords: cerebral plasticity; cognition; fMRI; multiple sclerosis; neurophysiology
Abbreviations: AR = activation ratio; BA = Brodmann area; EDSS = Expanded Disability Status Scale; EPI = echo-planar
imaging; fMRI = functional MRI; HADS = Hospital Anxiety and Depression Scale; NART = National Adult Reading
Test; NBPV = normalized brain parenchymal volume; VF = verbal ¯uency
Introduction
Cognitive de®cits occur frequently in patients with multiple
sclerosis even early in the disease course (Rao et al., 1991).
These typically involve impairment of attention and execu-
tive functions, including decision making, error correction
and suppression of pre-potent or habitual responses (Feinstein
et al., 1992). However, these de®cits are not apparent in all
patients and, like other clinical measures, do not correlate
strongly with conventional MRI measures of cerebral disease
burden (Rao et al., 1989; Swirsky-Sacchetti et al., 1992;
Turchi and Sarter, 1997).
One possible reason for this is the adaptive reorganization
of brain function to compensate for impairments of function
in damaged cognitive networks (Muir et al., 1992; Cifelli
et al., 2002). There are several precedents for this. Functional
MRI (fMRI) studies of hand movement (Reddy et al., 2000)
and visual stimulation (Werring et al., 2000) in patients with
multiple sclerosis show enlarged brain networks. Studies
using memory tasks have demonstrated that potentially
adaptive cortical functional changes occur prior to clinical
expression of (familial) Alzheimer's disease (Bookheimer
et al., 2000; C.D.Smith et al., 2002) or temporal lobe
pathology (Dupont et al., 2000).
Multiple mechanisms may be involved in such adaptive
responses, but a signi®cant contribution probably comes from
changes in synaptic ef®ciency modulated by changes in local
neurotransmitter levels. For example, short-term plasticity in
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 the sensorimotor system is associated with a local decrease in
GABA (Levy et al., 2002) and is impaired by increasing
GABAergic tone (Bute®sch et al., 2000). The cholinergic
system also may have effects relevant to brain recovery.
Animal studies have demonstrated that acetylcholine release
modulates activity in many neural pathways, including those
involved in attention and executive functions (Everitt and
Robbins, 1997). Some effects may be mediated by the
ampli®cation of responses to task-relevant stimuli (Everitt
and Robbins, 1997; Turchi and Sarter, 1997; Sarter et al.,
1999; Himmelheber et al., 2001). Prolonging the neuronal
excitatory period could be useful in the treatment of multiple
sclerosis in which functional impairment occurs both as a
consequence of structural pathology (e.g. axonal loss; Trapp
et al., 1998; Evangelou et al., 2000) and of reduced temporal
coherence of neuronal ®ring as a consequence of demyelina-
tion (Smith and McDonald, 1999). Recent data suggesting
bene®cial effects of cholinesterase inhibition in the treatment
of patients with diseases as varied as Alzheimer's disease,
multi-infarct dementia and multiple sclerosis argues for very
general clinical bene®ts (Freo et al., 2002). Studies in healthy
subjects suggest that cholinergic afferents may facilitate use-
dependent plasticity (Sawaki et al., 2002).
Here we wished to test ®rst whether functional reorganiza-
tion potentially could contribute to limiting cognitive de®cits
accompanying diffuse brain injury from multiple sclerosis.
We chose to employ the counting Stroop task (Stroop, 1935;
Bush et al., 1998) as a probe. Subjects with frontal lobe
damage perform poorly on the Stroop task (Perret, 1974;
Vendrell et al., 1995; Stuss et al., 2001). We hypothesized
that multiple sclerosis patients performing the task with
accuracy and speed similar to healthy controls would recruit
distinct or additional prefrontal cortical regions as an adaptive
response to underlying brain injury and that, re¯ecting this,
the extent of any abnormal prefrontal cortical recruitment
would correlate with their disease burden.
We then wished to test whether any altered pattern of brain
activity in patients was modulated acutely by cholinergic
agonism. We chose to test for this using rivastigmine, a
cholinesterase inhibitor, because it represents a form of
clinically practical chronic treatment (Freo et al., 2002). A
recent study has also suggested that treatment with donezepil
(a related acetylcholinesterase inhibitor) improves cognition
and behaviour in patients with multiple sclerosis (Greene
et al., 2000).
Subjects and methods
Subjects
Study of the Stroop effect in multiple sclerosis
patients and controls
Ten right-handed patients (seven women, three men; median
age 42 years, range 31±54 years) with clinically de®nite
multiple sclerosis (eight relapsing±remitting, two secondary
progressive; median duration 10 years, range 5±21 years)
according to the Poser criteria (Poser et al., 1983) and
subjective complaints of poor concentration or memory were
included in the study. Disability was assessed with the
Kurtzke Expanded Disability Status Scale (EDSS) (median
EDSS 2, range 0±6) (Kurtzke, 1983) at the time of the fMRI
scanning by an experienced neurologist. None had experi-
enced a relapse or treatment with steroids in the preceding
two months. Eleven right-handed, age (median age 42 years,
range 26±61 years) and sex (seven women, four men)
matched healthy subjects also were studied as controls.
Rivastigmine study
Five of the patients (three women, two men; median age 42
years, range 39±51 years; median duration of disease 10
years, range 6±17 years; median EDSS 2.5, range 2±6)
consented to participate in a trial testing the effects of
rivastigmine on patterns of brain activation with the Stroop
task. Four of the healthy subjects (three men, one woman;
median age 37 years, range 26±51 years) also agreed to
undergo the same test of rivastigmine effects. Each subject
was studied on two separate days: once with administration of
rivastigmine (3 mg orally) and once with administration of
placebo 150 min before fMRI scanning. To minimize the
side-effects of rivastigmine (which can cause nausea), all
subjects also were administered 3 mg of domperidone orally
once daily for 2 days before each fMRI scanning session, with
an additional 3 mg at the same time that rivastigmine or
placebo was taken on the day of fMRI scanning. The order of
administration of rivastigmine or placebo was pseudo-
randomized across trials to counterbalance the design.
Neither the investigator nor the subjects knew whether
placebo or rivastigmine was being administered. The image
®les also were coded so that the investigator was not aware of
the agent administered in any study until the ®nal stage of the
data analysis. Subjects had been told that they could
experience nausea and were asked to report any perceived
effects of the agent administered.
Data from four of the patients and from two of the controls
acquired during the placebo arm of the rivastigmine study
were included in the initial analysis of the Stroop effect in
multiple sclerosis patients and controls. These subjects were
chosen as those who were administered placebo at their ®rst
visit so that their experience was otherwise comparable tothat
of the other subjects in the Stroop effect study.
Approval was obtained for this study from the Oxford
Regional Ethics Committee (OxREC). Written informed
consent was obtained from all the subjects prior to their
participation in the study.
Neuropsychological battery
A brief neuropsychological battery was completed outside of
the scanner before the imaging study to characterize the
cognitive pro®le of subjects: (i) National Adult Reading Test
(NART) (Nelson, 1991); (ii) phonemic and categorical verbal
¯uency tests (i.e. FAS/animals) (Majors and Meyers, 1991);
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 (iii) Rey Complex Figure (Majors and Meyers, 1991); (iv)
Hopkins Verbal Learning TestÐRevised (Warrington, 1984);
(v) Symbol Digit Modality Test (Warrington, 1984); (vi)
Digit Span (Wechsler) (Warrington, 1984); (vii) set I: Ravens
Advanced Progressive Matrices (Warrington, 1984); and
(viii) Letter Number Sequencing (Wechsler) (Warrington,
1984).
Raw data scores for each test were converted to Z scores by
referring to normative data from the appropriate manuals or
reference materials. A `FAS de®cit' was calculated by
subtracting the FAS verbal ¯uency (VF) score obtained
from a predicted `premorbid' FAS score that can be derived
from the NART (Crawford et al., 1992) (a negative score
representing an actual VF score below the predicted VF
score). The Hospital Anxiety and Depression Scale (HADS)
(Zigmond and Snaith, 1983) also was administered.
Paradigm
The study used the counting Stroop task (Bush et al., 1998).
Subjects were presented with sets of between one and four
words presented on a screen as a vertical list every 1.5 s. The
words (balanced for across groups length) could be animal
words (`cat', `dog', `bird' or `mouse') (neutral trials) or
number words (`one', `two', `three' or `four') (interference
trials). Eight 30-s neutral blocks alternated with eight 30-s
interference blocks. A 30-s rest period was included at the
start and at the end.
Stimulus presentation
The visual stimuli were generated using in-house software
and projected onto a screen (In Focus LP1000; National
Projector, Dallas, TX, USA) 2.5 m from the head of the
patient. Subjects wore prism glasses to enable them to see the
screen. The stimuli were printed in sans serif black font 3 cm
in height. A four-button box was used by the subjects to
indicate the number of words on the screen and to record
reaction times.
The mean reaction time for each of the eight neutral and
interference blocks and the magnitude of the Stroop effect
(mean interference reaction time±mean neutral reaction time)
were calculated for each neutral/interference block. Incorrect
button-box responses were not included when calculating the
reaction times. A mean Stroop effect was calculated across all
eight of the paired neutral/interference blocks.
It was assumed initially that reaction times measured by the
button press re¯ect speeds of cognitive processing. To test
this in patients with multiple sclerosis, we compared
performance on the manual and oral subtests of the Symbol
Digit Modality Test. We found similar good correlations
between the Z scores obtained with the manual and oral
responses in both subject groups. We also did not observe any
signi®cant difference in the variance of the neutral reaction
times between patients and controls (data not shown), further
validating use of button press reaction time as an estimate of
relative cognitive processing speed for both groups.
Image acquisition
All scans were performed using a 3.0 Tesla whole body
scanner with a Varian Inova console and a quadrature
birdcage radiofrequency head coil. A 9-min echo-planar
imaging (EPI) sequence was used to acquire the fMRI data
[21 3 6 mm axial slices, echo time (TE) = 30 ms, repetition
time (TR) = 3000 ms, ®eld of view (FOV) = 256 3 256 mm,
matrix = 64 3 64]. A T1-weighted anatomical scan was
acquired for each subject [64 3 2 mm axial slices, TR = 30
ms, inversion time (TI) = 500 ms, TE = 5 ms, ¯ip angle = 15,
FOV = 256 3 256 mm, matrix = 256 3 256]. A proton-
density image also was acquired (spin echo, 30 3 4 mm axial
slices, TE = 15.5 ms, TR = 3750 ms, FOV = 256 3 160 mm,
matrix = 256 3 160). In one patient the latter could not be
acquired due to technical dif®culties.
Normalized brain parenchymal volume
Cross-sectional atrophy measures were performed using
SIENAX (www.fmrib.ox.ac.uk/fsl) (S.M.Smith et al., 2002)
with the T1-weighted anatomical images, which has a test±
retest error of 0.5±1% (S.M.Smith et al., 2002). The
normalized brain volumes for the patients were adjusted for
age using previously generated data from healthy controls to
calculate the age-adjusted normalized brain parenchymal
volume (NBPV).
Lesion segmentation
Lesion volume quanti®cation was performed manually on the
proton density images using DISPLAY (courtesy of Professor
A. Evans, Montreal Neurological Institute) by an observer
blinded to the clinical status of the patient. The mean (SD)
percentage intra-rater lesion volume measurement variation
was 4.1% (2.8%).
Image analysis
Analysis of the fMRI data was carried out using FMRI Expert
Analysis Tool, version 4 (FEAT) (www.fmrib.ox.ac.uk/fsl).
The following pre-statistics processing steps were applied:
motion correction using MCFLIRT (Jenkinson and Smith,
2001), spatial smoothing using a Gaussian kernel of full width
half maximum (FWHM) 5 mm, mean-based intensity
normalization of all volumes by a constant factor and high-
pass ®ltering (Gaussian-weighted LSF straight line ®tting,
with sigma = 50.0 s). Statistical analysis was carried out using
FMRIB's Improved Linear Model (FILM) with local
autocorrelation correction (Woolrich et al., 2001). All
probability values reported are corrected for multiple com-
parisons. The statistical images generated were related to
2752 A. M. M. Parry et al.
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 each the brain anatomy of each subject by registration with
the individual T1-weighted structural scan.
To identify the main effects of the Stroop task on brain
activation, an analysis of the patient and control groups
combined was performed (interference±neutral contrast).
Two `between-group' analyses were performed to determine
whether there were differences in brain activations with the
Stroop task (interference±neutral contrast) between the two
groups: (i) patients±controls; and (ii) controls±patients. All
group analyses were performed using a random-effects
model, with Z (Gaussianized T) statistic images thresholded
using clusters determined by Z > 2.0 and a (corrected) cluster
signi®cance of P = 0.05 (Worsley et al., 1992; Friston et al.,
1994; Forman et al., 1995). The high-resolution T1-weighted
images from the subjects were co-registered into standard
space (Talairach and Tournoux, 1988) and averaged to
produce a mean control and a mean patient structural image
on which the thresholded Z statistic images were overlaid.
This allowed assessment of activation areas in terms of
anatomical landmarks (based on correspondence to structures
in the Duvernoy atlas; Duvernoy, 1995) as well as reporting
the Talaraich co-ordinates of peak activations within each
anatomically de®ned area (Talairach and Tournoux, 1988).
The co-ordinates were transformed from the standard space of
the Montreal Neurological Institute (MNI) standard brain to
Talaraich space using an automated estimator (www.mrc-
cbu.cam.ac.uk/imaging).
Statistics
A multivariate analysis of variance (MANOVA) was used to
determine the effect of group (patient or control) on the size
of the Stroop effect and the Stroop error rate. A repeated
measures ANOVA was used to determine whether there was
an effect of time on the size of the Stroop effect. The
Spearmann's correlation coef®cient was used to relate change
in signal intensity to behavioural or structural MRI indices. A
corrected, two-tailed P value <0.05 was considered statis-
tically signi®cant. All statistics were performed using SPSS
for Windows (version 9.0).
Results
Patients and controls had comparable
performance in the counting Stroop task
Performance on the counting Stroop task was similar for the
patients and healthy controls. The mean reaction times were
only non-signi®cantly longer for the patients (controls 677
ms, range 514±1138 ms, and patients 734 ms, range 515±
1083 ms, for the neutral task, P = 0.28; controls 777 ms, range
583±1196 ms, and patients 852 ms, range 527±1167 ms, for
the interference task, P = 0.65). The mean Stroop effect in the
patient group was ~30% smaller than in the controls, but this
difference was not statistically signi®cant (controls, median
118 ms, range 56±272 ms; patients, median 78 ms, range 13±
151 ms, P = 0.09). There also were no clear differences in the
error rates for the task between the patient and control groups
(controls, median 2.0%, range 0.0±5.9%; patients, median
2.1%, range 1.3±12.8%, P = 0.81). There was no relationship
between the size of the Stroop effect and either the age-
corrected, NBPV, a measure of disease burden (Rudick et al.,
1999; S.M.Smith et al., 2002), or the T2-weighted MRI white
matter lesion loads in the patients. A repeated measures
ANOVA showed a reduction in the magnitude of the Stroop
effect in individual trial blocks over the course of the
experiment (Greenhouse-Geisser, F = 3.62, P = 0.02), but the
reduction was not different between patients and controls
(time/group interaction, F = 1.02, P > 0.38).
A distributed network of activation is associated
with counting Stroop task performance
Results from patients and controls initially were combined in
a random-effects group analysis to identify the main effect of
the counting Stroop task (interference±neutral contrast). As
described in previous reports (Bush et al., 1998; Carter et al.,
1998), we found signi®cant task-associated activations in
brain regions including bifrontal, biparietal and anterior
cingulate cortices (Table 1, Fig. 1). The maximum percentage
signal intensity change (interference±neutral contrast) in
these regions of interest correlated positively with the
magnitude of the Stroop effect (r = 0.49, P = 0.02).
Table 1 Areas of signi®cant activation during the Stroop
task (interference±neutral contrast) in a random-effects
combined group analysis of patients and healthy controls
Anatomical region Talairach co-ordinates
of maximum Z score
Maximum
Z score
xyz
Inferior frontal gyrus L ±40 16 8 4.9
Middle frontal gyrus L ±38 8 21 4.7
Intraparietal sulcus L ±25 ±67 26 4.3
Inferior pre-central sulcus L ±40 ±3 24 4.2
Inferior pre-central sulcus R 36 3 23 4.1
Cingulate sulcus L ±3 12 39 4.1
Superior parietal lobe L ±47 ±42 36 4.1
Inferior frontal gyrus R 22 1 17 3.9
Inferior temporal gyrus L ±40 ±32 ±21 3.8
Anterior insula L ±24 24 10 3.8
Middle occipital lobe R ±10 ±69 44 3.7
Middle frontal gyrus R 23 4 33 3.7
Superior frontal gyrus L ±13 8 51 3.6
Basal ganglia (caudate) L ±48 28 5 3.6
Superior frontal gyrus R 8 3 56 3.5
Supramarginal gyrus R 43 ±46 38 3.5
Anterior insula R 33 6 ±11 3.4
Intraparietal sulcus R 20 ±62 35 3.3
Anterior cingulate gyrus R 6 22 22 3.3
Anterior cingulate gyrus L ±8 24 20 3.2
L = left; R = right.
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 Patients showed greater predominantly left
medial prefrontal activation than controls
There also were differences in the patterns of activation
between the patient and healthy control groups. A random-
effects contrast of the interference±neutral conditions for
patients±controls identi®ed a predominantly left medial
frontal region corresponding to Brodmann area (BA) 8/9/10
with greater activity in the patients than controls (corrected P
< 0.001, maximum Z score = 3.5, 1638 voxels) (Table 2,
Fig. 2). The cluster de®ned at this threshold extended across
several frontal lobe areas and included distinct maxima in the
left middle frontal gyrus/superior frontal sulcus and in the left
and right superior frontal gyri. The anatomical location of the
peak Z score within this left frontal region for each patient
was determined by reference to their individual T1-weighted
structural image. The peak Z score was located in the left
superior frontal sulcus in ®ve patients, the left superior frontal
gyrus in four patients and the left middle frontal gyrus in one
patient.
The maximum percentage signal intensity changes for the
left medial frontal activation cluster were signi®cantly higher
in the patients than for the controls (patients, median 0.71%,
range 0.22±1.15%; controls, median 0.26%, range 0.20±
0.39%, P = 0.002). The maximum signal intensity changes for
this activation cluster were correlated (r = 0.71, P = 0.02)
with the magnitude of the Stroop effect for the patients
(Fig. 3). The maximum signal intensity changes in this region
of interest showed no correlation with the magnitude of the
Stroop effect for the controls.
Table 2 Areas of signi®cant activation during the Stroop
task (interference±neutral contrast) in random-effects
group contrasts between patients-controls and controls-
patients
Anatomical region Talairach co-ordinates
of maximum Z score
Maximum
Z score
xy z
Patients±controls
Middle frontal gyrus
L/superior frontal sulcus L
±20 12 36 3.5
Superior frontal gyrus L ±11 43 23 3.4
Superior frontal sulcus L ±24 24 47 3.2
Superior frontal gyrus R 6 39 42 2.4
Controls±patients
Basal ganglia (caudate) R 20 12 14 4.1
Inferior frontal gyrus R
(pars opercularis)
40 20 6 3.8
Putamen R 29 ±1 ±9 3.0
Fig. 1 Areas of signi®cant activation during the Stroop task (interference±neutral contrast) in a random-
effects combined group analysis of patients and healthy controls. Group random-effects Z maps are
superimposed onto an average high resolution scan of all subjects. Cross hairs are situated at the local
maximum Z score in the left inferior frontal gyrus. The anatomical locations and co-ordinates for the
local activation maxima are shown in Table 1.
Fig. 2 A mixed-effects contrast of brain regions activated during
the Stroop task (interference±neutral contrast) in patients±controls
identi®ed a signi®cant cluster predominantly in the left frontal
lobe. Within this cluster were distinct activation peaks in (A, B)
the left middle frontal gyrus/left superior frontal sulcus (±20, 12,
36) and (C, D) the left superior frontal gyrus (±11, 43, 23). Group
random-effects Z maps are superimposed onto average high-
resolution scan from the ten patients. Cross hairs are situated at
the local maximum Z score in each image.
2754 A. M. M. Parry et al.
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 To test whether this largely left medial prefrontal acti-
vation in the patients was a consequence of the (non-
signi®cantly) longer reaction time to the stimuli (as distinct
from cognitive processing more speci®cally associated with
the Stroop effect), we tested for a relationship between the
maximum signal intensity change in this cluster region in the
neutral±rest contrast and the mean neutral reaction time. No
correlation was found (r = 0.44, P = 0.20).
Controls had greater right frontal activation
than patients
A random-effects analysis contrasting controls±patients was
performed for the interference±neutral contrast. A signi®cant
cluster (corrected P = 0.004, maximum Z score = 4.1, 1191
voxels) was found with distinguishable local activation
maxima in the pars operculum of the right inferior frontal
gyrus (BA 45) and in the right basal ganglia (Table 2, Fig. 4).
The maximum percentage signal intensity changes for this
right inferior frontal cluster were signi®cantly higher in the
healthy controls than in the patient group (controls, median
0.55%, range 0.26±1.09%; patients, median 0.19%, range
0.08±0.33%, P < 0.001). There was no correlation between
the magnitude of the Stroop effect and the maximum signal
intensity change (interference±neutral contrast) in this region
of interest for either the controls or the patients.
Larger changes in brain activation relative to
controls were found in patients with greater
brain atrophy
For each patient, an activation ratio (AR) was calculated
expressing the magnitude (mean signal intensity change) of
the largely left medial prefrontal activation (unique to the
patients) relative to activation in right frontal region and
(reduced in the patients). A low AR thus was characteristic of
controls and higher AR values were characteristic of the
patients. There was an inverse correlation between AR and
the age-adjusted NBPV (r = ±0.72, P = 0.02) for the patient
group (Fig. 5). A similar relationship was not found for the
controls. However, data from the patients did not show a
signi®cant relationship between the AR value and either the
whole brain white matter lesion load (r = 0.32, P = 0.41) or
the lesion load in the right frontal white matter (r = 0.23, P >
0.55).
The different patterns of activation in controls
and patients observed during the interference±
neutral contrast were not due to differences in
`baseline' signal intensity changes in the
neutral task relative to rest
We tested whether the group activation differences for the
interference±neutral contrast could have arisen from differ-
ences in relative brain activity during the neutral±rest
contrast, i.e. whether the relative reduction of activity in the
right hemisphere in the patient group during the interference±
neutral task was due to a high `baseline' (neutral±rest)
activation. However, there was no signi®cant difference
between maximum signal changes for the patient or control
groups in either the right inferior frontal or the predominantly
left medial prefrontal regions of interest.
Stroop activation changes correlate with
neuropsychological de®cits in patients
A battery of neuropsychological tests was administered to
both subject groups (see Subjects and methods). There was no
signi®cant difference in the frequency of anxiety or depres-
sive symptoms between patients and healthy controls. There
was a signi®cant difference in neuropsychological test scores
between patients only for phonemic VF (FAS) [patients,
mean (SD) Z score ±0.87 (1.03); controls, mean (SD) Z score
0.50 (1.45), P = 0.05; relative FAS de®cit score for patients,
mean (SD) ±9.60 (8.33); FAS de®cit for controls, mean (SD)
1.20 (14.98), P = 0.04]. The FAS de®cit score correlated
inversely (r = ±0.83, P < 0.001) with AR for the patients,
although there was no signi®cant relationship between the
FAS de®cit and AR for the controls.
Rivastigmine normalized patterns of brain
activation in patients during the counting
Stroop task
To test for potential cholinergic modulation of the abnormal,
disease-associated pattern of brain activation in the patients,
rivastigmine effects were studied in ®ve patients and in four
healthy controls. Each subject was studied on two occasions
Fig. 3 Correlation between the size of the Stroop effect (ms) and
the maximum percentage signal intensity change between the
interference and the neutral conditions in the predominantly left
frontal region (identi®ed in the patient±control, random-effects
group analysis) in patients (®lled squares; r = ±0.71, P = 0.02) and
controls (open squares; P > 0.05).
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 and administered either oral rivastigmine or placebo 150 min
before fMRI scanning in a double-blinded fashion.
Only mild adverse effects were reported. Two patients and
two controls complained of feeling light-headed ~90 min
after taking a rivastigmine tablet. One patient complained of
feeling light-headed ~60 min after taking the placebo tablet.
There was a mean 56% lower maximum signal intensity
change in the predominantly left medial prefrontal region of
interest with the Stroop task after rivastigmine administration
compared with placebo (relative signal intensities: median
drug 0.36%, range 0.21±1.06%; median placebo 0.80%,
range 0.72±1.21%) for the patients. This was associated with
a mean 34% increase in maximum signal intensity in the right
inferior frontal region of interest (relative signal intensities:
median drug 0.32%, range 0.23±0.69%; median placebo
0.21%, range 0.17±0.86%) for the patients (Fig. 6). The AR
was calculated from counting Stroop fMRI data for each
patient both after being given rivastigmine or placebo. The
median AR for the patients decreased by a mean 74% on
rivastigmine relative to placebo (median AR drug 1.0, range
0.8±2.1; median AR placebo 3.9, range 2.5±8.9; Greenhouse-
Geisser, F = 6.53, P = 0.05). A decrease in AR with
rivastigmine treatment was observed in ®ve out of ®ve of the
patients.
To determine whether this effect was speci®c for the
patient group, brain activity also was contrasted in four
healthy controls receiving either placebo or rivastigmine. In
contrast to the patients, there was no change in AR in any of
the controls after rivastigmine administration (median AR
drug 0.9, range 0.5±1.6; median AR placebo 1.1, range 0.4±
1.6) (Fig. 6).
Comparison of results from patients or healthy controls
who received no intervention with those who received
placebo shows no effect of the placebo on AR.
The small size of the population in this pilot study
prevented meaningful testing for behavioural responses to
rivastigmine. However, no signi®cant differences between
accuracy or speed of responses in the rivastigmine and
placebo trials could be de®ned (Greenhouse Geisser, F =
0.37, P = 0.57) for either patients or controls.
Discussion
Our ®rst novel observation is that multiple sclerosis patients
and age-matched, healthy controls activate distinct brain
regions during the counting Stroop test, despite similar task
performance. When contrasted with the healthy controls, the
multiple sclerosis patients show greater activation primarily
in the left middle frontal gyrus/left superior frontal sulcus and
bilateral superior frontal gyrus (BA 8/9/10). When contrasted
with the patients, the controls show greater activation in the
right inferior frontal cortex (BA 45) and in the right basal
ganglia. The patients did not show signi®cant cognitive
impairment. The recruitment of additional brain regions in
the patients suggests that functional plasticity may contribute
to maintaining this relatively normal cognitive behaviour.
The extent of the differences in the patterns of brain
activation observed in the multiple sclerosis patients (de®ned
by the AR) is correlated with NBPV, a measure of total brain
disease burden (Rudick et al., 1999; S.M.Smith et al., 2002).
Fig. 4 A mixed-effects contrast of brain regions activated during the Stroop task (interference±neutral contrast) in controls-patients
revealed a cluster extending over the opercular surface of right frontal lobe and right basal ganglia. Distinct activation maxima were found
in the opercular surface of the right inferior frontal gyrus (38, 20, 6) and the right basal ganglia (20, 12, 14). Cross hairs are situated over
the local maximum Z score in the right inferior frontal lobe.
Fig. 5 Correlation between NBPV and the AR. A best-®t trend
line is superimposed on the data points from the patients (r =
±0.72, P = 0.02). No correlation was found for the controls. Filled
squares, patients; open squares, controls.
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 This suggests that the potentially adaptive functional changes
are responses to disease-associated brain injury.
The functional relevance of the predominantly left medial
frontal recruitment to the interference task for the patients
was demonstrated by the signi®cant relationship between the
maximum signal change in this region of interest and the
magnitude of the Stroop effect. There was no correlation in
the relative signal intensity change in this region between the
neutral±rest contrast and the neutral reaction time. Similar
activations in the left middle and superior frontal gyri have
been observed in healthy controls with other cognitive tasks
requiring generation of an internal response, inhibition with
selection of a response from among alternatives or self-
monitoring while maintaining multiple contingencies on-line
(Schlosser et al., 1998; Leung et al., 2000; Ruff et al., 2001).
We propose that the larger activation for patients in this
region is related to the need for increased internal perform-
ance monitoring as the relative impairment of primary
processing functionally relevant to task performance in-
creases with greater disease burden.
Although not signi®cant, there was a trend towards a
reduction in the Stroop effect, despite previous reports of an
increased Stroop effect in patients with multiple sclerosis
(Pujol et al., 2001; Vitkovitch et al., 2002). This difference
may re¯ect differences in the distribution of lesions in the
brain for patients in the different studies. Patients with lesions
predominantly in the right parietal lobe may have a reduced
Stroop effect, for example (Pujol et al., 2001).
Our second observation is that a single 3-mg dose of the
cholinesteraseinhibitor,rivastigmine(adrugthatcanenhance
aspects of cognition in different neurodegenerative and
vascular diseases; Freo et al., 2002), led to normalization of
the abnormal patterns of brain activation in the multiple
sclerosis patients. This observation was consistent for all of
the patients examined and not found for the healthy controls.
This suggests that the functional changes in patients are
modulated by cholinergic agonism and that they occur rapidly.
Right prefrontal cortex activity in the Stroop
response is reduced in the patients
During the Stroop task, subjects must selectively attend to the
task-relevant dimension of the stimulus while ignoring the
stronger (and con¯icting) task-irrelevant dimension. The
prefrontal cortex is thought to play a critical role in this task
by providing `top-down' control to favour the processing of
the task-relevant stimuli in the presence of more salient
stimuli and to represent and maintain task demands needed
for cognitive control (Miller et al., 1998; Brass et al., 2001).
The right lateral prefrontal cortex speci®cally appears to
mediate this behavioural inhibition (Miller and Cohen, 2001):
fMRI activation in the right inferior frontal lobe and basal
ganglia during the Stroop task has been observed consistently
in previous studies of healthy subjects (Peterson et al., 1999;
Leung et al., 2000). The ipsilateral basal ganglia shows strong
connectivity to the prefrontal cortex and may process related
functions in automating behaviour (Miller and Cohen, 2001) or
in modulation of the motor output (Gehring and Knight, 2000).
Activation in this right prefrontal region is reduced in
multiple sclerosis patients. As fMRI activation is related to
local neuronal synaptic activity (Lauritzen, 2001; Logothetis,
2002), in the context of disease reduced activity likely results
from the brain pathology. Consistent with this, fMRI activity
was related to relative mean brain volume, which in this case
is a measure of diffuse, irreversible pathology. The lack of
correlation between activity changes and the alternative
measure of disease burden provided by MRI lesion load is not
surprising given the weak relation of this non-speci®c index
of pathology to measures of functional impairment or
disability and the relatively greater extent of the total injury
burden found in the normal-appearing white matter (Miller
et al., 1998; Evangelou et al., 2000). Speci®cally relevant
pathology may involve functional `disconnection' with
Fig. 6 A scatter plot showing AR values for individual subjects
with no agent administered and after either placebo or
rivastigmine administration. These data demonstrate show how the
mean AR for patients is greater than for the healthy controls on
placebo (or with no agent), but in the control range after
rivastigmine administration. Decrease in AR with rivastigmine
were found with ®ve patients. However, no drug effect was seen
in any of the healthy controls. These data also con®rm that
placebo treatment did not change the AR from that for subjects
given no agent.
Rivastigmine modulates adaptive functional changes 2757
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 neuronal or axonal damage (Evangelou et al., 2000; Cifelli
et al., 2002). Alternatively, demyelination could alter the
summation of responses contributing to the blood oxygen
level-dependent (BOLD) signal (i.e. change the relationship
between time-averaged neuronal and haemodynamic re-
sponses by decreasing the temporal coherence of neuronal
®ring) (Smith and McDonald, 1999).
Distributed activation increases in the patients
as an adaptive response to brain injury
We hypothesize that the abnormal recruitment of the
predominantly left medial frontal brain regions observed in
the patients is an adaptive response to the brain injury from
multiple sclerosis. In principle, such an adaptive response
may be mediated by altered synaptic ef®ciency, `unmasking'
of latent pathways (Sanes et al., 1988; Jacobs and Donoghue
1991) or formation of new local connections (Li et al., 1998).
The acute modulation of this response by rivastigmine (see
below) suggests that the latter is less likely. To our
knowledge, this is the ®rst time that potential functional
reorganization potentially able to contribute to maintaining
cognitive performance despite pathological changes has been
reported with multiple sclerosis.
Action of rivastigmine in patients
The reduction in the AR in patients with rivastigmine
administration was a result both of a decrease in the fMRI
activation in the predominant left medial frontal region of
interest and an increase in the fMRI activation in the right
prefrontal region of interest. Acetylcholine-containing neu-
rons project diffusely through the brain and modulate activity
by increasing neuronal responsiveness to excitatory input
(Mesulam et al., 1986; McGaughy et al., 2000). We propose
that the primary effect of the drug-induced increase in
acetylcholine is to facilitate brain processing associated with
the right prefrontal activation. Adaptive responses in the
predominantly left frontal cortex regions then decrease in
consequence.
An earlier PET study (Furey et al., 1997) examining the
effects of physostigmine (an acetylcholinesterase inhibitor)
on a visual working memory task in healthy control subjects
demonstrated reduced task-associated activation in the right
middle frontal gyrus, a region of the frontal cortex charac-
teristically activated by this task. In this case, reduced
functional activation was interpreted as re¯ecting improve-
ments in task performance. A subsequent fMRI study using a
cholinesterase inhibitor in patients with Alzheimer's disease
showed both increases and decreases in regionally speci®c,
task-associated activations (Rombouts et al., 2002). As they
were accompanied by behavioural gains, the preferred
interpretation was these changes re¯ected increases in
activity in essential processing regions and decreases in
activity in regions with adaptive responses.
We did not observe improvements in any of the
behavioural outcome measures (e.g. a reduction in the size
of the Stroop effect with rivastigmine). The drug could alter
cortical processing without changing performance, as has
been observed in previous functional imaging studies
(Kimberg et al., 2001; Mattay et al., 2002). However, the
group of subjects studied was small and the power to detect a
behavioural effect was low. An earlier, somewhat larger,
study reported improvements in measures of cognitive
function in multiple sclerosis patients treated with donezepil,
an acetylcholinesterase inhibitor (Greene et al., 2000).
Conclusions
Overall, our results show that patients and controls have
signi®cant differences in the regions of the prefrontal cortex
activated during the counting Stroop task, despite showing
similar Stroop effects behaviourally. The magnitude of the
brain activation differences is strongly related to a global
MRI measure of disease burden in the patients. The pattern of
change suggests that cortical plasticity with recruitment of
medial prefrontal cortex may adaptively compensate for
functional impairment of in patients (Lee et al., 2000).
De®ning factors contributing to this potential functional
plasticity may be important for understanding the relationship
between the disease burden in multiple sclerosis and
neuropsychological consequences. We have identi®ed one
candidate factor by demonstration of effects of rivastigmine,
which increases cholinergic agonism. The acute response to
this drug also suggests that the plasticity characterized here
may not demand structural reorganization, emphasizing the
potential importance of `unmasking' of latent pathways.
Results suggest that cholinergic agonism could improve at
least symptoms related to executive function and attention in
multiple sclerosis patients. It is possible that this, in addition
to possible effects on basal ganglia circuits (Chaudhuri and
Behan, 2000), could also contribute to improvement of
symptoms of fatigue.
Acknowledgements
We wish to thank Dr Leigh Nystrom for a critical review of
the manuscript. P.M.M. and J.P. gratefully acknowledge the
support of the Multiple Sclerosis Society of Great Britain and
Northern Ireland (510/U23998). Work in the FMRIB Centre
is supported by a grant from the MRC to P.M.M. (G9409531).
P.M.M. and J.P. acknowledge an unrestricted research
donation from Novartis Pharmaceuticals.
References
Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-
Vance MA, Mazziotta JC, et al. Patterns of brain activation in
people at risk for Alzheimer's disease. New Engl J Med 2000; 343:
450±6.
Brass M, Zysset S, von Cramon DY. The inhibition of imitative
response tendencies. Neuroimage 2001; 14: 1416±23.
Bush G, Whalen PJ, Rosen BR, Jenike MA, McInerney SC, Rauch
SL. The counting Stroop: an interference task specialized for
2758 A. M. M. Parry et al.
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 functional neuroimaging±validation study with functional MRI.
Hum Brain Mapp 1998; 6: 270±82.
Bute®sch CM, Davis BC, Wise SP, Sawaki L, Kopylev L, Classen
J, et al. Mechanisms of use-dependent plasticity in the human motor
cortex. Proc Natl Acad Sci USA 2000; 97: 3661±5.
Carter CS, Braver TS, Barch DM, Botvinick MM, Noll D, Cohen
JD. Anterior cingulate cortex, error detection, and the online
monitoring of performance. Science 1998; 280: 747±9.
Chaudhuri A, Behan PO. Fatigue and basal ganglia. J Neurol Sci
2000; 179: 34±42.
Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM.
Thalamic neurodegeneration in multiple sclerosis. Ann Neurol
2002; 52: 650±3.
Crawford JR, Moore JW, Cameron IM. Verbal ¯uency: a NART-
based equation for the estimation of premorbid performance. Br J
Clin Psychol 1992; 31: 327±9.
Dupont S, Van de Moortele PF, Samson S, Hasboun D, Poline JB,
Adam C, et al. Episodic memory in left temporal lobe epilepsy: a
functional MRI study. Brain 2000; 123: 1722±32.
Duvernoy HM. The human brain stem and cerebellum. Wien:
Springer-Verlag; 1995.
Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM.
Quantitative pathological evidence for axonal loss in normal
appearing white matter in multiple sclerosis. Ann Neurol 2000;
47: 391±5.
Everitt BJ, Robbins TW. Central cholinergic systems and cognition.
Annu Rev Psychol 1997; 48: 649±84.
Feinstein A, Kartsounis LD, Miller DH, Youl BD, Ron MA.
Clinically isolated lesions of the type seen in multiple sclerosis: a
cognitive, psychiatric, and MRI follow up study. J Neurol
Neurosurg Psychiatry 1992; 55: 869±76.
Forman SD, Cohen JD, Fitzgerald M, Eddy WF, Mintun MA, Noll
DC. Improved assessment of signi®cant activation in functional
magnetic resonance imaging (fMRI): use of a cluster-size threshold.
Magn Reson Med 1995; 33: 636±47.
Freo U, Pizzolato G, Dam M, Ori C, Battistin L. A short review of
cognitive and functional neuroimaging studies of cholinergic drugs:
implications for therapeutic potentials. J Neural Transm 2002; 109:
857±70.
Friston K, Worsley KJ, Frackowiak RS, Mazziotta JC, Evans AC.
Assessing the signi®cance of focal activations using their spatial
extent. Hum Brain Mapp 1994; 1: 210±20.
Furey ML, Pietrini P, Haxby JV, Alexander GE, Lee HC, VanMeter
J, et al. Cholinergic stimulation alters performance and task-speci®c
regional cerebral blood ¯ow during working memory. Proc Natl
Acad Sci USA 1997; 94: 6512±6.
Gehring WJ, Knight RT. Prefrontal-cingulate interactions in action
monitoring. Nat Neurosci 2000; 3: 516±20.
Greene YM, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S, et al.
A 12-week, open trial of donepezil hydrochloride in patients with
multiple sclerosis and associated cognitive impairments. J Clin
Psychopharmacol 2000; 20: 350±6.
Himmelheber AM, Sarter M, Bruno JP. The effects of
manipulations of attentional demand on cortical acetylcholine
release. Brain Res Cogn Brain Res 2001; 12: 353±70.
Jacobs KM, Donoghue JP. Reshaping the cortical motor map by
unmasking latent intracortical connections. Science 1991; 251:
944±7.
Jenkinson M, Smith S. A global optimisation method for robust
af®neregistrationofbrainimages.MedImageAnal2001;5:143±56.
Kimberg DY, Aguirre GK, Lease J, D`Esposito M. Cortical effects
of bromocriptine, a D-2 dopamine receptor agonist, in human
subjects, revealed by fMRI. Hum Brain Mapp 2001; 12: 246±57.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology 1983; 33:
1444±52.
Lauritzen M. Relationship of spikes, synaptic activity, and local
changes of cerebral blood ¯ow. J Cereb Blood Flow Metab 2001;
21: 1367±83.
Lee M, Reddy H, Johansen-Berg H, Pendlebury S, Jenkinson M,
Smith S, et al. The motor cortex shows adaptive functional changes to
brain injury from multiple sclerosis. Ann Neurol 2000; 47: 606±13.
Leung HC, Skudlarski P, Gatenby JC, Peterson BS, Gore JC. An
event-related functional MRI study of the stroop color word
interference task. Cereb Cortex 2000; 10: 552±60.
Levy LM, Ziemann U, Chen R, Cohen LG. Rapid modulation of
GABA in sensorimotor cortex induced by acute deafferentation.
Ann Neurol 2002; 52: 755±61.
Li Y, Jiang N, Powers C, Chopp M. Neuronal damage and plasticity
identi®ed by microtubule-associated protein 2, growth-associated
protein 43, and cyclin D1 immunoreactivity after focal cerebral
ischemia in rats. Stroke 1998; 29: 1972±80.
Logothetis NK. The neural basis of the blood-oxygen-level-
dependent functional magnetic resonance imaging signal. Philos
Trans R Soc Lond B Biol Sci 2002; 357: 1003±37.
Majors JE, Meyers KR. Rey Complex Figure Completion. Odessa
(FL): Psychological Assessment Resources; 1991.
Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE,
Chase TE, et al. Dopaminergic modulation of cortical function in
patients with Parkinson's disease. Ann Neurol 2002; 51: 156±64.
McGaughy J, Everitt BJ, Robbins TW, Sarter M. The role of
cortical cholinergic afferent projections in cognition: impact of new
selective immunotoxins. Behav Brain Res 2000; 115: 251±63.
Mesulam MM, Volicer L, Marquis JK, Mufson EJ, Green RC.
Systematic regional differences in the cholinergic innervation of the
primate cerebral cortex: distribution of enzyme activities and some
behavioral implications. Ann Neurol 1986; 19: 144±51.
Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of
magnetic resonance techniques in understanding and managing
multiple sclerosis. Brain 1998; 121: 3±24.
Miller EK, Cohen JD. An integrative theory of prefrontal cortex
function. Annu Rev Neurosci 2001; 24: 167±202.
Muir JL, Dunnett SB, Robbins TW, Everitt BJ. Attentional
functions of the forebrain cholinergic systems: effects of
Rivastigmine modulates adaptive functional changes 2759
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 intraventricular hemicholinium, physostigmine, basal forebrain
lesions and intracortical grafts on a multiple-choice serial reaction
time task. Exp Brain Res 1992; 89: 611±22.
Nelson HE. National Adult Reading Test (NART). 2nd ed. Windsor
(UK): NFER-Nelson; 1991.
Perret E. The left frontal lobe of man and the suppression of
habitual responses in verbal categorical behaviour.
Neuropsychologia 1974; 12: 323±30.
Peterson BS, Skudlarski P, Gatenby JC, Zhang H, Anderson AW,
Gore JC. An fMRI study of Stroop word-color interference:
evidence for cingulate subregions subserving multiple distributed
attentional systems. Biol Psychiatry 1999; 45: 1237±58.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA,
Ebers GC, et al. New diagnostic criteria for multiple sclerosis:
guidelines for research protocols. Ann Neurol 1983; 13: 227±31.
Pujol J, Vendrell P, Deus J, Junque C, Bello J, Marti-Vilalta JL,
et al. The effect of medial frontal and posterior parietal
demyelinating lesions on stroop interference. Neuroimage 2001;
13: 68±75.
Rao SM, Leo GJ, Haughton VM, Aubin-Faubert P, Bernardin L.
Correlation of magnetic resonance imaging with
neuropsychological testing in multiple sclerosis. Neurology 1989;
39: 161±6.
Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction
in multiple sclerosis. I. Frequency, patterns, and prediction.
Neurology 1991; 41: 685±91.
Reddy H, Narayanan S, Arnoutelis R, Jenkinson M, Antel J,
Matthews PM, et al. Evidence for adaptive functional changes in the
cerebral cortex with axonal injury from multiple sclerosis. Brain
2000; 123: 2314±20.
Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in
brain activation during cholinergic enhancement with rivastigmine
in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 73:
665±71.
Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain
parenchymal fraction to measure whole brain atrophy in relapsing-
remitting MS. Multiple Sclerosis Collaborative Research Group.
Neurology 1999; 53: 1698±704.
Ruff CC, Woodward TS, Laurens KR, Liddle PF. The role of the
anterior cingulate cortex in con¯ict processing: evidence from
reverse stroop interference. Neuroimage 2001; 14: 1150±8.
Sanes JN, Suner S, Lando JF, Donoghue JP. Rapid reorganization of
adult rat motor cortex somatic representation patterns after motor
nerve injury. Proc Natl Acad Sci USA 1988; 85: 2003±7.
Sarter M, Bruno JP, Turchi J. Basal forebrain afferent projections
modulating cortical acetylcholine, attention, and implications for
neuropsychiatric disorders. Ann NY Acad Sci 1999; 877: 368±82.
Sawaki L, Boroojerdi B, Kaelin-Lang A, Burstein AH, Bute®sch
CM, Kopylev L, et al. Cholinergic in¯uences on use-dependent
plasticity. J Neurophysiol 2002; 87: 166±71.
Schlosser R, Hutchinson M, Joseffer S, Rusinek H, Saarimaki A,
Stevenson J, et al. Functional magnetic resonance imaging of
human brain activity in a verbal ¯uency task. J Neurol Neurosurg
Psychiatry 1998; 64: 492±8.
Smith CD, Andersen AH, Kryscio RJ, Schmitt FA, Kindy MS,
Blonder LX, et al. Women at risk for AD show increased parietal
activation during a ¯uency task. Neurology 2002; 58: 1197±202.
Smith KJ, McDonald WI. The pathophysiology of multiple
sclerosis: the mechanisms underlying the production of symptoms
and the natural history of the disease. Philos Trans R Soc Lond B
Biol Sci 1999; 354: 1649±73.
Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico
A, et al. Accurate, robust, and automated longitudinal and cross-
sectional brain change analysis. Neuroimage 2002; 17: 479±89.
Stroop JR. Studies of interference in serial verbal reactions. J Exp
Psychol 1935; 18: 643±61.
Stuss DT, Floden D, Alexander MP, Levine B, Katz D. Stroop
performance in focal lesion patients: dissociation of processes and
frontal lobe lesion location. Neuropsychologia 2001; 39: 771±86.
Swirsky-Sacchetti T, Mitchell DR, Seward J, Gonzales C, Lublin F,
Knobler R, et al. Neuropsychological and structural brain lesions in
multiple sclerosis: a regional analysis. Neurology 1992; 42: 1291±5.
Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human
brain. Stuttgart: Thieme; 1988.
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L.
Axonal transection in the lesions of multiple sclerosis. New Engl J
Med 1998; 338: 278±85.
Turchi J, Sarter M. Cortical acetylcholine and processing capacity:
effects of cortical cholinergic deafferentation on crossmodal
divided attention in rats. Brain Res Cogn Brain Res 1997; 6:
147±58.
Vendrell P, Junque C, Pujol J, Jurado MA, Molet J, Grafman J. The
role of prefrontal regions in the Stroop task. Neuropsychologia
1995; 33: 341±52.
Vitkovitch M, Bishop S, Dancey C, Richards A. Stroop interference
and negative priming in patients with multiple sclerosis.
Neuropsychologia 2002; 40: 1570±6
Warrington EK. Recognition Memory Test. Windsor (UK): NFER-
Nelson; 1984.
Werring DJ, Bullmore ET, Toosy AT, Miller DH, Barker GJ,
MacManus DG, et al. Recovery from optic neuritis is associated
with a change in the distribution of cerebral response to visual
stimulation: a functional magnetic resonance imaging study. J
Neurol Neurosurg Psychiatry 2000; 68: 441±9.
Woolrich MW, Ripley BD, Brady M, Smith SM. Temporal
autocorrelation in univariate linear modeling of FMRI data.
Neuroimage 2001; 14: 1370±86.
Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional
statistical analysis for CBF activation studies in human brain. J
Cereb Blood Flow Metab 1992; 12: 900±18.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale.
Acta Psychiatr Scand 1983; 67: 361±70.
Received April 21, 2003. Revised June 29, 2003
Accepted July 8, 2003
2760 A. M. M. Parry et al.
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 